Medizinische Universität Graz - Research portal
Zebisch Armin |
Presentations at scientific and public conferences
Alihodžić, D; Özkaya, E; Foßelteder, J; Sconocchia, T; Auinger, L; Schlenke, P; Sill, H; Zebisch, A; Wölfler, A; Vujić, N; Kratky, D; Reinisch, A
Investigating the contribution of TET2 mutant human clonal hematopoiesis to human atherosclerotic plaque formation in a novel LDLR/ApoE double knock-out mouse model.
Doctoral Day 2024; 08.02.2024; Graz, AUSTRIA. 2024.
[Poster]
Alihodžić, D; Özkaya, E; Foßelteder J; Sconocchia, T; Auinger, L; Schlenke, P; Sill, H; Zebisch, A; Wölfler A; Vujić, N; Kratky, D; Reinisch A
CRISPR/Cas9 genome engineering to model TET2 mutant human clonal hematopoiesis and its pro-atherogenic potential.
Austrian Atherosclerosis Society (AAS) Annual Meeting; MAI 2-4, 2024; St. Gilgen, AUSTRIA. 2024.
[Poster]
ALIHODŽIĆ, D; ÖZKAYA1, E; PABST, G; FOßELTEDER, J; SCONOCCHIA, T; AUINGER, L; SCHLENKE, P; SILL1, H; ZEBISCH, A; WÖLFLER, A; REINISCH, A
Modeling SRSF2/TET2 mutational cooperativity in CMML development
European Hematology Association (EHA) 2024 Hybrid Congress; JUNE 13-16, 2024; Madrid, SPAIN. 2024.
[Poster]
Clemo, N; Roman-Trufero, M; Auner, H; Butt, R; Zebisch, A; Chaida, P; Herzog, S; Fuchter, M
Efficacy of GCN2 inhibition by a novel small molecule AP030 in acute leukemia.
J CLIN ONCOL. 2024; 42(16):
[Poster]
Web of Science
Dutta, S; Rezania, S; Lyssy, F; Lind, K; Vosberg, S; Thallinger, G; Zebisch, A; Wölfler, A; Pabst, G; Foßelteder, J; Reinisch, A; Sill, H;
Deciphering the molecular mechanism of mesenchymal stromal cell mediated drug resistance in acute myeloid leukemia.
29th European Hematology Association Congress; JUN 13-16, 2024; Madrid, SPAIN. 2024.
[Poster]
Foßelteder, J; Brauchart, T; Schlacher, A; Sconocchia, T; Özkaya, E; Auinger, L; Schlenke, P; Sill, H; Zebisch, A; Reinisch, A;
Engineered cytokine-expressing mesenchymal stromal cells support ex vivo culture of human HSPCs and AML cells.
BMS Future Talks; SEP 27-28, 2024; Vienna, AUSTRIA. 2024.
[Poster]
Lind, K; Dutta, S; Foßelteder, J; Pabst, G; Reinisch, A; Wölfler, A; Zebisch, A; Sill, H;
Deciphering early steps of TP53 aberrant human leukemogenesis.
29th European Hematology Association Congress; JUN 13-16, 2024; Madrid, SPAIN. 2024.
[Poster]
Özkaya, E; Sconocchia, T; Foßelteder, J; Alihodzic, D;
Schlacher, A; Auinger, L; Schlenke, P; Sill, H; Zebisch, A; Reinisch, A
Genome engineered TET2 loss-of-function mutations increase stem cell self-renewal in human hematopoietic stem and progenitor cells.
Doctoral Day (DocDay); FEB 08 2024; Graz, Austria. 2024.
[Poster]
Zebisch, A
Akute myeloische Leukämie und Myelodysplastische Syndrome
WISSENSCHAFTLICHE HIGHLIGHTS ASH 2023; Jan 18, 2024; Graz. 2024.
[Oral Communication]
Zebisch, A
RAS-signaling in myeloid neoplasms: from bedside to bench and back again
1. Alpe Adria Hematology Meeting 2024; MAR 15-15, 2024; Graz, AUSTRIA. 2024.
[Oral Communication]
Zebisch, A
Chronic myelomonocytic leukemia with mutations in RAS and inactivation of EZH2
Cancer Research Day; Nov 16, 2024; Graz. 2024.
[Oral Communication]
Zebisch, A
Fokus auf LR-MDS: Translationale Daten und Biologie der Substanzen
Frühjahrstagung der österreichischen Gesellschaft für Hämatologie und Medizinische Onkologie; Apr 4-6, 2024; Wien. 2024.
[Oral Communication]
Zebisch, A
Nicht intensive Therapie der AML mit Fokus auf orale Substanzen
Frühjahrstagung der österreichischen Gesellschaft für Hämatologie und Medizinische Onkologie; APR 4-6, 2024; Wien. 2024.
[Oral Communication]
Zebisch, A
Nicht intensive Therapie der AML
Hämatologie Meeting Ost/Süd; Nov 11-12, 2024; Semmering. 2024.
[Oral Communication]
Zebisch, A
Therapie der AML 2024: Intensive Erstlinientherapie
Frühjahrstagung der Österreichischen Gesellschaft für Hämatologie und Medizinische Onkologie; APR 4-6, 2024; Wien. 2024.
[Oral Communication]
Bürger, M; Amor, M; Akhmetshina, A; Bianco, V; Weichhart, T; Perfler, B; Zebisch, A; Kratky, D
Elucidating the Consequences of Loss of MMP12 in Lysosomal Acid Lipase Deficiency.
DK-MCD: 13th Scientific Retreat; SEP 26, 2023; Seggau, Austria. 2023.
[Poster]
Ghaffari Tabrizi-Wizsy, N; Connolly, S; Szmyra, M; Chaida, P; Hysa, P; Haingartner S; Deutsch, A; Zebisch, A; Strobl, H
The avian chorioallantois membrane as a 3R model to study immunoncology
The Austrian Society for Allergology and Immunology - Annual Meeting 2023; SEP 14-16. 2023; Linz. 2023.
[Poster]
FullText
Lyssy, F; Lind, K; Zöscher, F; Zebisch, A; Wölfler, A; Pabst, G; Fosselteder, J; Reinisch, A; Sill, H; Dutta, S
Modelling drug resistance conferred by mono- and bi-allelic TP53 aberrations using isogenic AML cell lines
ONCOL RES TREAT. 2023; 46: 188-189.
[Poster]
Web of Science
FullText
Zebisch, A
MDS Biologie: neue und translationale Aspekte
Frühjahrstagung der Österreichischen Gesellschaft für Hämatologie und Medizinische Onkologie; MAR 30- APR 1, 2023; Innsbruck. 2023.
[Oral Communication]
Zebisch, A
Myelodysplastisches Syndrom: Highlights ASH 2022
Wissenschaftliche Highlights ASH 2022; JAN 19, 2023; Graz. 2023.
[Oral Communication]
Zebisch, A
WHO Klassifikation & ICC für MDS 2022 – was ist neu, was heißt dies für die Praxis?
Frühjahrstagung der Österreichischen Gesellschaft für Hämatologie und Medizinische Onkologie; MAR 30 - APR 1, 2023; Innsbruck. 2023.
[Oral Communication]
Zebisch, A
Acute myeloid leukemia - state of the art
New Persepctives in Hematology; FEB 9, 2023; Graz. 2023.
[Oral Communication]
Zebisch, A
Erstlinientherapie-Algorithmus: Was ist Standard für welche Patienten?
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie; OKT 13-16, 2023; Hamburg. 2023.
[Oral Communication]
Bürger, M; Amor, M; Akhmetshina, A; Bianco, V; Perfler, B; Zebisch, A; Kratky, D
Elucidating the Consequences of MMP12 Loss in Lysosomal Acid Lipase Deficiency
DK-MCD 12th Scientific Retreat; OCT 19, 2022; Schloss Seggau, Austria. 2022.
[Poster]
Bürger, M; Amor, M; Akmetshina, A; Bianco, V; Perfler, B; Zebisch, A; Kratky, D
Elucidating the Consequences of MMP12 Loss in Lysosomal Acid Lipase Deficiency
45th ELC Meeting ; AUG 8, 2022; Tutzing, GERMANY. 2022.
[Oral Communication]
Dutta,S; Moritz,J; Pregartner,G; Thallinger,G; Brandstätter, I; Lind,K; Rezania,S; Lyssy,F; Reinisch,A; Zebisch,A; Berghold,A;Wölfler, A and Sill, H
AML and MDS patients with TP53 aberrations – a single cancer center experience.
Magazine of European Medical Oncology“. 2022; -Frühjahrestagung ÖGHO 2022; APR 8-10 2022; Graz, Austria.
[Oral Communication]
Lembeck, A; Zebisch, A; Quehenberger, F; Wolfler, A
Pravalenz von Pilz- und Fisch-formigen Erythrozyten in verschiedenen hamatologischen Erkrankungen
ONCOL RES TREAT. 2022; 45(SUPPL 2):290-291.
[Poster]
Web of Science
Pabst, G; Foßelteder, F; Schlacher, A; Auinger, L; Martinez-Krams, D; Ediriwickrema, A; Kashofer, K; Beham-Schmid, Ch; Greinix, HT; Woelfler, A; Schlenke, P; Sill, H; Zebisch, A; Majeti, R; Reinisch, A;
Modeling the Development of SRSF2 Mutated Myeloid Malignancies By CRISPR/Cas9 Mediated Genome Engineering of Primary Human Hematopoietic Stem and Progenitor Cells.
Blood (2021) 138 (Supplement 1): 2160.. 2022; 138: 2160-2160.-ASH Annual Meeting 2021; DEZ 11-14, 2021; Atlanta, USA.
[Poster]
FullText
Pleyer, L; Vaisband, M; Pfeilstocker, M; Stauder, R; Heibl, S; Sill, H; Girschikofsky, M; Stampfl-Mattersberger, M; Tinchon, C; Hartmann, BL; Petzer, A; Schreder, M; Schmitt, CA; Vallet, S; Melchardt, T; Scagnetti, L; Zebisch, A; Machherndl-Spandl, S; Wolf, D; Keil, F; Hasenauer, J; Greil, R
Cox Proportional Hazards Deep Neural Network Identifies Peripheral Blood Complete Remission (PB-CR) to be at Least Equivalent to Morphologic CR in Predicting Outcomes of Patients Treated with Azacitidine - a Prospective Cohort Study By the AGMT
BLOOD. 2022; 140: 1346-1349.
Doi: 10.1182/blood-2022-168521
[Oral Communication]
Web of Science
FullText
FullText_MUG
Telebar, F; Berg, JL; Perfler, B; Bramreiter, B; Caraffini, V; Prokesch, A; Geissler, K; Penz, T; Schuster, M; Reinisch, A; Wölfler, A; Sill, H; Zebisch, A;
Co-occurrence of mutations modifying RAS and EZH2 inactivation in chronic myelomonocytic leukemia causes amplification of RAS-AKT signaling and increases the sensitivity to AKT inhibitors
Proceedings of the Annual Meeting of the Austrian Society of Haematology and Medical Oncology. memo 15 (Suppl 3), 37–67 (2022). . 2022; 15( ):S65--OeGHO- & AHOP-Frühjahrstagung 2022; April 8-10, 2022; Graz, Austria.
[Oral Communication]
FullText
Zebisch, A
Myelodysplastisches Syndrom: Highlights ASH 2020
Wissenschaftliche Highlights ASH 2021; JAN 20, 2022; Graz. 2022.
[Oral Communication]
Berg, JL; Perfer, B; Hatzl, S; Reinisch, A; Pregartner, G; Klymiuk, I; Tierling, S; Geissler, G; Strobl, H; Berghold, A; Wölfer, A; Sill, H; Zebisch, A
Aberrant expression of micro-RNA-125a plays a role in the pathogenesis and treatment of chronic myelomonocytic leukemia – Update
memo - Proceedings of the Annual Meeting of the Austrian Society
of Haematology and Medical Oncology. 2021; 14: -Annual Meeting of the Austrian Society
of Haematology and Medical Oncology; APR 8-10, 2021; Wien.
[Poster]
Foßelteder, J; Schlacher, A; Pabst, G; Amtmann, B; Schöll, W; Kashofer, K; Beham-Schmid, C; Schlenke, P; Greinix, HT; Sill, H; Woelfler, A; Zebisch, A; Reinisch, A
Introduction and Genetic Correction of Calreticulin Mutations in Human Hematopoietic Stem and Progenitor Cells Sheds Light on MPN Pathogenesis
Blood. 2021; 138(S1):-Annual Meeting of the American Society of Hematology (ASH); DEC 11-14, 2021; Atlanta, USA.
Doi: 10.1182/blood-2021-147919
[Poster]
Web of Science
FullText
FullText_MUG
Pabst, G; Foßelteder, J; Schlacher, A; Auinger, L; Martinez-Krams3, D; Ediriwickrema, A; Kashofer, K; Beham-Schmid, C; Greinix, HT; Woelfler, A; Schlenke, P; Sill, H; Zebisch, A; Majeti, R; Reinisch, A
Modeling the Development of SRSF2 Mutated Myeloid Malignancies By CRISPR/Cas9 Mediated Genome Engineering of Primary Human Hematopoietic Stem and Progenitor Cells
Blood. 2021; 138(S1):-Annual Meeting of the American Society of Hematology (ASH); DEC 11-14, 2021; Atlanta, USA.
Doi: 10.1182/blood-2021-149591
[Poster]
Web of Science
FullText
FullText_MUG
Pleyer, L; Pfeilstocker, M; Stauder, R; Heibl, S; Sill, H; Girschikofsky, M; Stampfl-Mattesberger, M; Tinchon, C; Hartmann, B; Petzer, A; Petricevic, B; Schmitt, CA; Vallet, S; Geissler, K; Sperr, WR; Leisch, M; Egle, A; Melchardt, T; Piringer, G; Zebisch, A; Machherndl-Spandl, S; Wolf, D; Keil, F; Angermann, H; Drost, M; Larcher-Senn, J; Greil, R
Peripheral Blood Complete Remission Provides Added Value to the Classical Definition of Morphologic Complete Remission – a Prospective Cohort Study of 1441 Patients with MDS, CMML and AML Treated within the Austrian Azacitidine Registry
Englisch. 2021; 138(S1):-Annual Meeting of the American Society of Hematology (ASH); DEC 11-14, 2021; Atlanta, USA.
Doi: 10.1182/blood-2021-145401
[Poster]
Web of Science
FullText
FullText_MUG
Zebisch, A
AML Rezidivprävention: Prophylaktisch oder MRD-getriggert?
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie; OCT 1-4, 2021; Berlin, GERMANY. 2021.
[Oral Communication]
Zebisch, A
Myelodysplastische Syndrome: Highlights ASH 2020
post-ASH Wrap up; JAN 21, 2021; Graz. 2021.
[Oral Communication]
Zebisch, A
Leukämieforschung - der Weg zur personalisierten Therapie
Generalversammlung Leukämiehilfe Steiermark; OCT 07, 2021; Graz. 2021.
[Science to Public]
Zebisch, A
RAS Inhibition - der Weg zur personalisierten Therapie
SAMSUNG SDI Battery Systems - Forschungsvortrag; OCT 20, 2021; Premstätten. 2021.
[Science to Public]
Zebisch, A
MDS: neue Therapien, neue Konzepte
New Perspectives in Hematology; NOV 11, 2021; Graz. 2021.
[Oral Communication]
Zebisch, A
Myelodysplastische Syndrome: Highlights ASH 2019.
post-ASH Wrap up; Jan 23, 2020; Graz. 2020.
[Oral Communication]
Berg, JL; Perfler, B; Hatzl, S; Reinisch, A; Geissler, K; Strobl, H; Wölfler, A; Sill, H; Zebisch, A
Expression of miR-125a is decreased in chronic myelomonocytic leukemia and of relevance for the treatment with 5-azacytidine
Proceedings of the Annual Meeting of the Austrian Society of Haematology and Medical Oncology, Magazine of European Medical Oncology. 2019; 12: 53--Annual Meeting of the Austrian Society of Haematology and Medical Oncology; APR 11-13, 2019; Linz, AUSTRIA.
[Poster]
Dutta S, Pregartner G, Rücker FR, Heitzer H, Zebisch A, Bullinger L, Berghold A, Döhner K, Sill H
Functional Classification of TP53 Mutations in Acute Myeloid Leukemia
Blood. 2019; 134, Suppl. 1: -American Society of Hematology, Annual Meeting; DEC 6-10, 2019; Orlando.
[Poster]
DuttaS, Pregartner G, Rücker F, Heitzer E,Zebisch A, Bullinger L,Berghold A, Döhner K Sill H
Functional Classification of TP53 Mutations in Acute Myeloid Leukemia
German-Austrian Acute Myeloid Leukemia study group (AML-SG) Study meeting ; May 23-24, 2019; Vienna, Austria. 2019.
[Oral Communication]
Pleyer L, Pfeilstocker M, Stauder R, Heibl S, Sill H, Girschikofsky M, Stampfl-Mattersberger M, Tinchon C, Petzer A, Schmitt CA, Vallet S, Mandac I, Geissler K, Sperr WR, Leisch M, Egle A, Melchardt T, Fusinato J, Piringer G, Zebisch A, Machherndl-Spandl S, Wolf D, Keil F, Greil R,
Expanding on Current Definitions of Hematologic Improvement in MDS, CMML and AML: Landmark Analyses of 1301 Patients Treated with Azacitidine in the Austrian Registry of Hypomethylating Agents By the AGMT-Study Group
Blood. 2019; 134, Suppl. 1: -American Society of Hematology, Annual Meeting; DEC 6-10, 2019; Orlando.
[Poster]
Ulz, P; Perakis, S; Zhou, Q; Moser, T; Belic, J; Lazzeri, I; Wölfler, A; Zebisch, A; Gerger, A; Pristauz, G; Petru, E; White, B; Roberts, C; St. John, J; Schimek, MG; Geigl, JB; Bauernhofer, T; Sill, H; Bock, C; Heitzer, E; Speicher,M
Inference of tumor cell-specific transcription factor binding from cell-free DNA enables tumor subtype prediction
Circulating Nucleic Acids in Plasma and Serum (CNAPS); SEP 23-25, 2019; Jerusalem, Israel. 2019.
[Poster]
FullText
Zebisch, A
Next Generation Sequencing in der Hämatologie - ein Leitfaden für Kliniker
Frühjahrstagung der österreichischen Gesellschaft für Hämatologie und medizinische Onkologie; APR 11-13, 2019; Linz, AUSTRIA. 2019.
[Oral Communication]
A. Muralikrishnan, A. Rosenberger, E. Schwarzenberger, H. Strobl, A. Zebisch, H. Sill, A. Wölfler
C/EBPα is crucial in early dendritic cell development
5th European Congress of Immunology. 2018; -5th European Congress of Immunology; September 2-5, 2018; Amsterdam, Netherlands.
[Oral Communication]
FullText
Caraffini, V; Geiger, O; Rosenberger, A; Hatzl, S; Perfler, B; Berg, JL; Lim, C; Strobl, H; Kashofer, K; Hoefler, G; Geissler, K; Kolch, W; Blyth, K; Athineos, D; Wolfler, A; Sill, H; Zebisch, A
Loss of RKIP expression is a frequent event in chronic myelomonocytic leukemia and functionally involved in the pathogenesis of this malignancy
ONCOL RES TREAT. 2018; 41: 27-27.
[Oral Communication]
Web of Science
Daga, S; Rosenberger, A; Krisper, N; Prietl, B; Reinisch, A; Zebisch, A; Sill, H; Wolfler, A
GPR56 and CLL-1 (CLEC12A) as putative leukemic stem cell markers in CD34-positive acute myeloid leukemia
ONCOL RES TREAT. 2018; 41: 73-73.
[Poster]
Web of Science
Daga, S; Rosenberger, A; Krisper, N; Reinisch, A; Zebisch, A; Sill, H; Wölfler, A
GPR56 is a putative marker of leukemic stem cells in CD34-positive acute myeloid leukemia.
Proceedings of the Annual Meeting of the Austrian Society of Haematology and Medical Oncology. 2018; Supplement 1/18: -Annual Meeting of the Austrian Society for Hematology and Medical Oncology; APR, 19-21, 2018; Villach, AUSTRIA.
[Poster]
Geissler, K; Barna, A; Jager, E; Gurbisz, M; Alendar, T; Ljubuncic, E; Jilch, R; Nosslinger, T; Pfeilstocker, M; Tuchler, H; Reisner, R; Sliwa, T; Keil, F; Geissler, C; Burgstaller, S; Thaler, J; Machherndl-Spandl, S; Zach, O; Weltermann, A; Bettelheim, P; Stauder, R; Borjan, B; Zebisch, A; Sill, H; Schwarzinger, I; Hormann, G; Jager, U; Sperr, WR; Knobl, P; Schneeweiss, B; Berger, J; Ohler, L; Ulsperger, E; Kusec, R; Germing, U; Valent, P
The role of RAS pathway hyperactivation in the progression and transformation of chronic myelomonocytic leukemia
ONCOL RES TREAT. 2018; 41: 238-238.
[Oral Communication]
Web of Science
Hatzl, S; Ebner, S; Perfler, B; Quehenberger, F; Troppmair, J; Reinisch, A; Wolfler, A; Sill, H; Zebisch, A
Deregulation of the micro-RNA-23a/TOP2B axis causes resistance to cytarabine in acute myeloid leukemia
ONCOL RES TREAT. 2018; 41: 243-243.
[Oral Communication]
Web of Science
Hatzl, S; Ebner, S; Perfler, B; Quehenberger, F; Troppmair, J; Reinisch, A; Wölfler, A; Sill, H; Zebisch, A
Increased expression of micro-RNA-23a causes resistance to cytarabine in acute myeloid leukemia.
Proceedings of the Annual Meeting of the
Austrian Society of Haematology and Medical Oncology
. 2018; Supplement 1/18: 26-26.-Annual Meeting of the Austrian Society for Hematology and Medical Oncology; APR, 19-21, 2018; Villach, AUSTRIA.
[Oral Communication]
Muralikrishnan, AS; Rosenberger, A; Schwarzenberger, E; Strobl, H; Zebisch, A; Sill, H; Wolfler, A
A role of C/EBP alpha in early dendritic cell development
ONCOL RES TREAT. 2018; 41: 102-102.
[Poster]
Web of Science
Pabst, G; Prochazka, K; Pregartner, G; Rücker, FG; Heitzer, E; Woelfler ,A; Zebisch, A; Berghold, A; Döhner, K; Sill H.
Impact of TP53 mutated subclones in acute myeloid leukemia
Blood. 2018; 132(Suppl ):-Annual Meeting of the American Society of Hematology; December 1-4, 2018; San Diego.
Doi: 10.1182/blood-2018-99-110667
[Poster]
Web of Science
FullText
FullText_MUG
Zebisch, A
Myelodysplastische Syndrome
Wissenschaftliche Highlights ASH ; JAN 18, 2018; Graz. 2018.
[Oral Communication]
Aberer, F; Holzgruber, J; Tripolt, NJ; Mader, JK; Pieber, TR; Greinix ,H; Zebisch, A; Woelfler, A; Sourij, H
A pilot trial to investigate efficacy and safety of an automized decision support system for the treatment of steroid induced hyperglycemia in patients with acute Graft-versus-host disease
Diabetes.. 2017; 66(S1):A669-A669.-77th Scientific Sessions of the American Diabetes Association (ADA); JUN 9-13, 2017; San Diego, CA, USA.
Aberer, F; Holzgruber, J; Tripolt, NJ; Zebisch, A; Greinix, H; Sill, H; Mader, JK; Pieber, TR; Wölfler, A; Sourij, H
Efficacy and safety of an insulin decision support system in the treatment of steroid hyperglycaemia in patients with graft-versus- host-disease: a randomised pilot trial.
Diabetologia. 2017; 60(S1):S323-S324.-53rd Annual Meeting of the European Association for the Study of Diabetes (EASD); SEP 11-15, 2017; Lisbon, PORTUGAL.
[Poster]
Web of Science
Aberer, F; Mader, JK; Stauber, M; Neumeister, P; Oulhaj, Abderrahim; Zebisch, A; Pieber, TR; Greinix, H; Sill, H; Woelfler, A; Sourij, H
Early Hyperglycemia after Initiation of Glucocorticoid Therapy Predicts Adverse Outcome in Patients with Acute Graft-vs.-Host Disease.
Diabetes.. 2017; 66(S1):A24-A25.-77th Scientific Sessions of the American Diabetes Association (ADA); JUN 9-13, 2017; San Diego, CA, USA.
[Oral Communication]
Aberer, F; Mader, JK; Stauber, M; Tripolt, N; Holzgruber, J; Zebisch, A; Pieber, TR; Neumeister, P; Greinix, H; Sill, H; Wölfler, A; Sourij, H
Early hyperglycaemia after initiation of glucocorticoid therapy predicts adverse outcome in patients with acute graft-versus-host disease.
4th International Hospital Diabetes Meeting. 2017; MAY 19-20, 2017; Atlanta, USA.
[Poster]
Caraffini, V; Geiger, O; Rosenberger, A; Hatzl, S; Perfler, B; Berg, JL; Lim, C; Strobl, H; Kashofer, K; Hoefler, G; Geissler, K; Kolch, W; Blyth, K; Athineos, D; Woelfler, A; Sill, H; Zebisch, A
LOSS OF RAF KINASE INHIBITOR PROTEIN IS INVOLVED IN MYELOMONOCYTIC LINEAGE COMMITMENT AND AGGRAVATES THE DEVELOPMENT OF CHRONIC MYELOMONOCYTIC LEUKEMIA IN A MURINE IN-VIVO MODEL
HAEMATOLOGICA. 2017; 102: 148-149.-22nd Congress of the European-Hematology-Association; JUN 22-25, 2017; Madrid, SPAIN.
[Oral Communication]
Web of Science
Caraffini, V; Geiger, O; Rosenberger, A; Hatzl, S; Perfler, P; Berg, JL; Lim, C; Strobl, H; Kashofer, K; Hoefler, G; Geissler, K; Kolch, W; Blyth, K; Athineos, D; Wölfler, A; Sill, H; Zebisch, A
RAF kinase inhibitor protein is involved in the development of chronic myelomonocytic leukemia
memo - Magazine of European Medical Oncology. 2017; 10(2):21-21.-Annual Meeting of the Austrian Society of Haematology and Medical Oncology; APR 6-8, 2017; Bregenz, AUSTRIA.
[Poster]
Caraffini, V; Schauer, S; Kashofer, K; Wolfler, A; Hoefler, G; Sill, H; Zebisch, A
RAF KINASE INHIBITOR PROTEIN IS INVOLVED IN THE DEVELOPMENT OF MYELOID SARCOMA
HAEMATOLOGICA. 2017; 102: 361-362.-22nd Congress of the European-Hematology-Association; JUN 22-25, 2017; Madrid, SPAIN.
[Poster]
Web of Science
Caraffini, V; Schauer, S; Kashofer, K; Wölfler, A; Hoefler, G; Sill, H; Zebisch A
Loss of RAF kinase inhibitor Protein in myeloid sarcoma
memo - Magazine of European Medical Oncology
. 2017; 10(2):31-31.-Annual Meeting of the Austrian Society of Haematology and Medical Oncology
; APR 6-8, 2017; Bregenz, AUSTRIA.
[Poster]
Daga, S; Krisper, N; Zebisch, A; Sill, H; Wölfler, A
GPR56 is a putative leukemic stem cell marker with prognostic significance in acute myeloid leukemia.
4th International Conference on Acute Myeloid Leukemia; OCT 5-7, 2017; Estoril, PORTUGAL. 2017.
[Poster]
Gaksch, L; Kashofer, K; Heitzer, E; Daga, S; Hofer, S; Krisper, N; Hofler, G; Zebisch, A; Sill, H; Wolfler, A
Persistence of non-DNMT3A mutations predicts relapse in cytogenetically normal AML
ONCOL RES TREAT. 2017; 40: 140-141.
[Oral Communication]
Web of Science
Geissler, K; Barna, A; Jäger, E; Alendar, T; Ljubuncic, E; Jilch, R; Nösslinger, T; Pfeilstöcker, M; Tüchler, H; Reisner, R; Sliwa, T; Keil, F; Burgstaller, S; Thaler, J; Machherndl-Spandl, S; Zach, O; Weltermann, A; Bettelheim, P; Stauder, R; Schwarzinger, I; Hörmann, G; Jäger, U; Sperr, RW; Knöbl, P; Schneeweiss, B; Berger, J; Kusec, R; Öhler, L; Zebisch, A; Sill, H; Germing, U; Valent, P
High spontaneous in-vitro myeloid colony growth is an adverse risk factor in chronic myelomonocytic leukemia
Oncol Res Treat. 2017; 40(S3):131-131.-Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie; SEP 29 - OCT 3, 2017; Stuttgart, GERMANY. (ISBN: 978-3-318-06110-9 )
[Oral Communication]
Web of Science
Kashofer, K; Gornicec, M; Caraffini, V; Lind, K; Schauer, S; Beham-Schmid, C; Wölfler, A; Hoefler, G; Sill, H; Zebisch, A
Genetic aberrations of myeloid sarcomas
memo - Magazine of European Medical Oncology
. 2017; 10(2):28-28.-Annual Meeting of the Austrian Society of Haematology and Medical Oncology
; APR 6-8, 2017; Bregenz, AUSTRIA.
[Poster]
Rollig C, Middeke JM, Stasik S, Zebisch A, Sill H, Kramer M, Scholl S, Hochhaus A, Edgar J, Brümmendorf TH, Naumann R, Steffen B, Serve H, Altmann H, Kunzmann V, Einsele H, Parmentier SB, Schaich M, Burchert A, Neubauer A, Heits F, Berdel WE, Sockel K, Stoelzel F, Platzbecker U, Ehninger G, Bornhäuser M, Schetelig J, and Thiede C.
Real World Data on Decitabine Treatment in 296 Patients with Acute Myeloid Leukemia: Outcome and Impact of TP53 Mutations
Blood. 2017; 130, suppl. 1: -American Society of Hematology; Dec7-12, 2017; Atlanta, USA.
[Poster]
Schmidt, V; Zebisch, A; Hofer, S; Steinwender, D; Höfler, G; Beham-Schmid, C; Sill, H; Wölfler, A
Analysis of criteria for tyrosine kinase Inhibitor discontinuation in CML patients in a real-life setting
memo - Magazine of European Medical Oncology. 2017; 10(2):26-26.-Annual Meeting of the Austrian Society of Haematology and Medical Oncology
; APR 6-8, 2017; Bregenz, AUSTRIA.
[Poster]
Stauber, M; Aberer, F; Oulhaj, A; Mader, JK; Zebisch, A; Pieber, TR; Neumeister, P; Greinix, HT; Sill, H; Sourij, H; Wolfler, A
Early hyperglycaemia after initiation of glucocorticoid therapy predicts adverse outcome in patients with acute graft-versus-host disease
BONE MARROW TRANSPL. 2017; 52: S285-S285.
Web of Science
Subramanian, A; Rosenberger, A; Schwarzenberger, E; Strobl, H; Zenisch, A; Sill, H; Wölfler, A
A role of C/EBPa in early dendritic cell development.
FEBS Immunology Summer School; SEP 23-30, 2017; Hvar, CROATIA. 2017.
[Poster]
Zebisch, A
Pathophysiologie und neue Targets bei MDS
Annual Meeting of the Austrian Society of Haematology and Medical Oncology
; APR 6-8, 2017; Bregenz, AUSTRIA. 2017.
[Oral Communication]
Zebisch, A
Best of Congress - Translational Research
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie; SEP 29 - OCT 3, 2017; Stuttgart, GERMANY. 2017.
[Oral Communication]
Aberer, F; Kremser, S; Zebisch, A; Mader, JK; Sill, H; Greinix, H; Zinke-Cerwenka, W; Pieber, TR; Oulhaj, A; Wölfler, A; Sourij, H
Hyperglycemia during the First Month after Allogeneic Hematopoietic
Stem Cell Transplantation Is an Independent Risk Factor for
Overall Survival in Patients with Acute Myeloid Leukemia.
Diabetes. 2016; 65(S1):A410-A411.-76th Scientific Sessions of the American Diabetes Association (ADA); JUN 10-14, 2016; New Orleans, LA, USA.
[Poster]
Aberer, F; Stauber, M; Zebisch, A; Greinix, H; Sill, H; Mader, JK; Oulhaj, A; Pieber, TR; Wölfler, A; Sourij, H
In-Hospital Hyperglycemia Is Associated with Adverse Outcome in
Patients with Acute or Chronic Graft vs. Host Disease after Hematopoeietic Stem Cell Transplantation.
Diabetes. 2016; 65(S1):A390-A390.-76th Scientific Sessions of the American Diabetes Association (ADA); JUN 10-14, 2016; New Orleans, LA, USA.
[Poster]
Bainschab, A; Quehenberger, F; Greinix, HT; Krause, R; Wölfler, A; Sill, H; Zebisch, A
Antibiotic prophylaxis is associated to a decreased rate of infections in AML patients treated with low-intensity therapeutic regimens
memo - Magazine of European Medical Oncology . 2016; 9(1):20-20.-Annual Meeting of the Austrian Society of Haematology and Medical Oncology; MAR 17-19, 2016; Vienna, AUSTRIA.
[Poster]
Gaksch, L; Kashofer, K; Daga, S; Hofer, S; Höfler, G; Zebisch, A; Sill, H; Wölfler A
Mutation clearance detected by parallel
sequencing at end of treatment: impact on
relapse-free survival in intermediate-risk AML
patients
memo - Magazine of European Medical Oncology . 2016; 9(1):3-3.-Annual Meeting of the Austrian Society of Haematology and Medical Oncology; MAR 17-19, 2016; Vienna, AUSTRIA.
[Oral Communication]
Gaksch, L; Kashofer, K; Heitzer, E; Daga, S; Hofer, S; Krisper, N; Höfler, G; Zebisch, A; Sill, H; Wölfler A
Persitence of non-DNMT3A mutations predicts relapse in cytogenetically normal AML.
Oncol Res Treat 2016. 2016; 39(suppl3):140--Jahrestagung DGHO; OCT 14-18,2016; Leipzig. (ISBN: 2296-5270 )
[Oral Communication]
Web of Science
Geissler, K; Barna, A; Jäger, E; Alendar, T; Ljubuncic, E; Jilch, R; Nösslinger, T; Pfeilstöcker, M; Tüchler, H; Reisner, R; Sliwa, T; Keil, F; Burgstaller, S; Thaler, J; Machherndl-Spandl, S; Zach, O; Weltermann, A; Bettelheim, P; Stauder, R; Schwarzinger, I; Hörmann, G; Jäger, U; Sperr, WR; Knöbl, P; Schneeweiss, B; Berger, J; Kusec, R; Öhler, L; Zebisch, A; Sill, H; Germing, U; Valent, P
Clinical, Hematological, and Biologic Characteristics in Chronic Myelomonocytic Leukemia Patients with a JAK2 V617F Mutation
Blood. 2016; 128(22):-Annual Meeting of the American Society of Hematology; DEC 3-6, 2016; San Diego, USA.
[Poster]
Geissler, K; Barna, A; Jäger, E; Alendar, T; Ljubuncic, E; Jilch, R; Nösslinger, T; Pfeilstöcker, M; Tüchler, H; Reisner, R; Sliwa, T; Keil, F; Burgstaller, S; Thaler, J; Machherndl-Spandl, S; Zach, O; Weltermann, A; Bettelheim, P; Stauder, R; Schwarzinger, I; Hörmann, G; Jäger, U; Sperr, WR; Knöbl, P; Schneeweiss, B; Berger, J; Kusec, R; Öhler, L; Zebisch, A; Sill, H; Germing, U; Valent P
High Spontaneous In Vitro Myeloid Colony Formation in Chronic Myelomonocytic Leukemia is Associated with Mutations in Rasopathy Genes, Myeloproliferation and Inferior Prognosis
Blood. 2016; 128(22):-Annual Meeting of the American Society of Hematology; DEC 3-6, 2016; San Diego, USA.
[Poster]
Lal, R; Lind, K; Kashofer, K; Heitzer, E; Ulz, P; Troppmair, J; Hofer, S; Schulz, E; Mathre, K; Wölfler, A; Zebisch, A; Sill, H
TP53 mutations in acute myeloid leukemia affect pre-leukemic stem cells
memo - Magazine of European Medical Oncology . 2016; 0(1):19-20.-Annual Meeting of the Austrian Society of Haematology and Medical Oncology; MAR 17-19, 2016; Vienna, AUSTRIA.
[Poster]
Olipitz, W; Lind, K; Monsberger, N; Katschnig, A; Mangerich, A; Rankl, J; Hofer, S; Mueller, M; Schulz, E; Quehenberger, F; Schlembach, D; Robier, C; Woelfler, A; Zebisch, A; Sill, H
IMPAIRED BASE EXCISION REPAIR GLYCOSYLASE/AP ENDONUCLEASE ACTIVITY CONTRIBUTES TO CYTARABINE RESISTANCE IN ACUTE MYELOID LEUKEMIA
HAEMATOLOGICA. 2016; 101: 211-212.
[Poster]
Web of Science
Stauber, M; Aberer, F; Zebisch, A; Neumeister, P; Greinix, HT; Sill, H; Sourij, H; Wölfler, A
Steroid-induced hyperglycemia adversely impacts outcome in graft-versus-host disease
memo - Magazine of European Medical Oncology . 2016; 9(1):21-21.-Annual Meeting of the Austrian Society of Haematology and Medical Oncology; MAR 17-19, 2016; Vienna, AUSTRIA.
[Poster]
Zebisch, A
MDS: klinische Risikostratifizierung und Therapie
Workshop Hämatopathologie; Jun 27, 2016; Graz. 2016.
[Oral Communication]
Zebisch, A
Myelodysplastische Syndrome
Post-ASH 2016, Neue wissenschaftliche Erkenntnisse Hämatoonkologie; JAN 28, 2016; Graz. 2016.
[Oral Communication]
Zebisch, A; Lal, R; Muller, M; Lind, K; Sill, H
TP53 germline mutations occur in acute myeloid leukemia and are associated with therapy-related cases following ionizing radiation
WIEN KLIN WOCHENSCHR. 2016; 128: S385-S386.
[Poster]
Web of Science
Aberer, F; Mader, JK; Kremser, S; Zinke-Cerwenka, W; Greinix, H; Pieber, TR; Zebisch, A; Sill, H; Oulhaj, A; Wölfler, A; Sourij, H
Glykämie nach allogener Stammzelltransplantation bei Patienten mit akuter myeloischer Leukämie (AML) ist ein unabhängiger Prädiktor für das Überleben.
Wiener Klinische Wochenschrift. 2015; 127(Suppl 4 ):S135-S135.-43. Jahrestagung der Österreichischen Diabetes Gesellschaft (ÖDG); NOV 19-21, 2015; Salzburg, AUSTRIA.
[Poster]
Web of Science
Bainschab, A; Quehenberger, F; Greinix, HT; Krause, R; Wolfler, A; Sill, H; Zebisch, A
Efficacy of antibiotic prophylaxis in AML patients treated with low-intensity therapeutic regimens
ONCOL RES TREAT. 2015; 38: 73-74.
[Poster]
Web of Science
Gaksch, L; Kashofer, K; Höfler, G; Tinchon, C; Krippl, P; Zebisch, A; Greinix, H; Sill, H; Wölfler, A
Feasibility of next generation sequencing for routine diagnostic genetic profiling in myeloid malignancies.
memo-magazine of european medical oncology; 2015 Proceedings of the Annual Meeting of the Austrian Society for Haematology and Medical Oncology.. 2015; 8(1):-Annual Meeting of the Austrian Society of Haematology and Medical Oncology; APR 23-25, 2015; Salzburg, AUSTRIA.
[Poster]
Hatzl, S; Geiger, O; Kuepper, MK; Seime, T; Nußbaumer, E; Wieser, R; Pichler, M; Scheideler, M; Nowek, K; Jongen-Lavrencic, M; Wölfler, A; Troppmair, J; Sill, H; Zebisch, A
Loss of the tumor- and metastasis suppressor RAF kinase inhibitor protein is caused by the overexpression of miRNA-23a
Oncology Research and Treatment. 2015; 38: -Annual Meeting of the German, Austrian and Swiss Associations of Hematology and Medical Oncology; OKT 9-13, 2015; Basel, SWITZERLAND. (ISBN: 978-3-318-02811-9 )
[Oral Communication]
Hatzl, S; Geiger, O; Kuepper, MK; Seime, T; Nussbaumer, E; Wieser, R; Pichler, M; Scheideler, M; Nowek, K; Jongen-Lavrencic, M; Wolfler, A; Troppmair, J; Sill, H; Zebisch, A
Loss of the tumor- and metastasis suppressor RAF kinase inhibitor protein is caused by the overexpression of miRNA-23a
ONCOL RES TREAT. 2015; 38: 99-99.
[Oral Communication]
Web of Science
Hatzl, S; Geiger, O; Nußbaumer, E; Rosenberger, A; Troppmair, J; Kolch, W; Blyth, K; Sill, H; Woelfler, A; Zebisch, A
RAF kinase inhibitor protein is involved in the myelomonocytic differentiation of hematopoietic progenitors.
memo-magazine of european medical oncology; 2015 Proceedings of the Annual Meeting of the Austrian Society for Haematology and Medical Oncology.. 2015; 8(S1):-Annual Meeting of the Austrian Society of Haematology and Medical Oncology; APR 23-25, 2015; Salzburg, AUSTRIA.
[Poster]
Kremser, S; Aberer, F; Zinke-Cerwenka, W; Neumeister, P; Zebisch, A; Greinix, H; Sill, H; Sourij, H; Wölfler, A
Hyperglycemia is an adverse risk factor in AML patients undergoing allogeneic hematopoietic stem cell transplantation.
memo-magazine of european medical oncology; 2014 Proceedings of the Annual Meeting of the Austrian Society for Haematology and Medical Oncology.. 2015; 8(S1):-Annual Meeting of the Austrian Society of Haematology and Medical Oncology; APR 23-25, 2015; Salzburg, AUSTRIA.
[Poster]
Milewska, M; Romano, D; Guerriero, ML; Birtwistle, M; Quehenberger, F; Hatzl, S; Herrero-Mier, A; Kholodenko, BN; Segatto, N; Kolch, W; Zebisch, A
Mitogen-inducible gene-6 inhibits malignant transformation of mutated BRAF by mediating feedback inhibition towards the epidermal growth factor receptor.
memo-magazine of european medical oncology; 2015 Proceedings of the Annual Meeting of the Austrian Society for Haematology and Medical Oncology.. 2015; 8(1):-Annual Meeting of the Austrian Society of Haematology and Medical Oncology; APR 23-25, 2015; Salzburg, AUSTRIA.
[Poster]
Nußbaumer, E; Hatzl, S; Kuepper, K; Geiger, O; Wieser, R; Pichler, M; Scheideler, M; Nowek, K; Lavrencic, M; Woelfler, A; Troppmair, J; Sill, H; Zebisch, A
Loss of RAF kinase inhibitor protein in acute myeloid leukemia is caused by the overexpression of miRNA-15a.
memo-magazine of european medical oncology; 2015 Proceedings of the Annual Meeting of the Austrian Society for Haematology and Medical Oncology.. 2015; 8(1):-Annual Meeting of the Austrian Society of Haematology and Medical Oncology; APR 23-25, 2015; Salzburg, VIENNA.
[Poster]
Pleyer, L; Burgstaller, S; Stauder, R; Girschikofsky, M; Sill, H; Schlick, K; Thaler, J; Halter, B; Machherndl-Spandl, S; Zebisch, A; Pichler, A; Pfeilstöcker, M; Autzinger, EM; Lang, A; Geissler, K; Voskova, D; Geissler, D; Sperr, WR; Hojas, S; Mandac-Rogulj, I; Andel, J; Greil, R
Is it time to redefine response or treatment failure in elderly patients with WHO-AML unfit for intensive chemotherapy?
Blood 2015. 2015; 126(23):-Annual meeting of the American Society of Hematology; DEC 5-8, 2015; Orlando, USA.
[Poster]
Web of Science
Pleyer, L; Burgstaller, S; Stauder, R; Girschikofsky, M; Sill, H; Schlick, K; Thaler, J; Halter, B; Machherndl-Spandl, S; Zebisch, A; Pichler, A; Pfeilstöcker, M; Autzinger, EM; Lang, A; Geissler, K; Voskova, D; Geissler, D; Sperr, WR; Hojas, S; Mandac-Rogulj, I; Andel, J; Greil, R
Azacitidine in acute myeloid leukemia with >30% bone marrow blasts and <15 G/L white blood cell count: Results from the Austrian Azacitidine Registry of the AGMT Study Group versus randomized controlled phase III clinical trial data.
Blood 2015. 2015; 126(23):-Annual Meeting of the American Society of Hematology; DEC 5-8, 2015; Orlando, USA.
[Poster]
Web of Science
Rosenberger, A; Geiger, O; Zebisch, A; Sill, H; Wolfler, A
C/EBP alpha-induced proinflammatory cytokines regulate early dendritic cell development
ONCOL RES TREAT. 2015; 38: 249-250.
[Poster]
Web of Science
Stauber, M; Aberer, F; Zebisch, A; Neumeister, P; Greinix, HT; Sill, H; Sourij, H; Wolfler, A
Steroid-induced hyperglycemia adversely impacts outcome in graft-versus-host disease
ONCOL RES TREAT. 2015; 38: 129-129.
[Poster]
Web of Science
Zebisch, A
Myelodysplastisches Syndrom
Onkologische Tagung; APR 29, 2015; Bad Erlach, AUSTRIA. 2015.
[Oral Communication]
Zebisch, A; Schulz, E; Hatzl, S; Grosso, M; Lombardo, B; Acierno, G; Sill, H; Iolascon, A
Epsilon-gamma-delta-beta° thalassemia Austrian I: identification of a novel hemoglobinopathy.
memo-magazine of european medical oncology; 2015 Proceedings of the Annual Meeting of the Austrian Society for Haematology and Medical Oncology.. 2015; 8(1):-Annual Meeting of the Austrian Society of Haematology and Medical Oncology; APR 23-25, 2015; Salzburg, AUSTRIA.
[Poster]
Kuepper, MK; Wolf, O; Huber-Krassnitzer, B; Wieser, R; Pichler, M; Scheideler, M; Woelfler, A; Sill, H; Zebisch, A
Overexpression of miR-23a, miR-24 and miR-15a in acute myeloid leukemia with loss of the RAF kinase inhibitor protein.
memo-magazine of european medical oncology 2014 Proceedings of the Annual Meeting of the Austrian Society for Haematology and Medical Oncology. 2014; 7(1):-Annual Meeting of the Austrian Society for Haematology and Medical Oncology; APR 10-12, 2014; Innsbruck, AUSTRIA.
[Oral Communication]
Lind, K; Olipitz, W; Monsberger, N; Katschnig, A; Hofer, S; Schulz, E; Quehenberger, F; Schlembach, D; Robier, C; Wölfler, A; Zebisch, A; Sill, H
Defizienz der Basen-Exzisions-Reparatur (BER) bei akuter myeloischer Leukämie (AML).
memo-magazine of european medical oncology
2014 Proceedings of the Annual Meeting of the Austrian Society for Haematology and Medical Oncology. 2014; 7(1):-Annual Meeting of the Austrian Society for Haematology and Medical Oncology; APR 10-12, 2014; Innsbruck, AUSTRIA.
[Poster]
Olipitz, W; Lind, K; Monsberger, N; Katschnig, A; Mangerich, A; Hofer, S; Schulz, E; Quehenberger, F; Schlembach, D; Robier, C; Woelfler, A; Zebisch, A; Sill, H
Base Excision Repair Glycosylase Activity Is Impaired in a Subgroup of Acute Myeloid Leukemia Resulting in Increased Levels of Oxidative Base Lesions
BLOOD. 2014; 124(21):-56th Annual Meeting of the American-Society-of-Hematology; DEC 06-09, 2014; San Francisco, CA.
[Poster]
Web of Science
Olipitz, W; Lind, K; Monsberger, N; Katschnig, A; Mangerich, A; Hofer, S; Schulz, E; Quehenberger, F; Schlembach, D; Robier, C; Wölfler, A; Zebisch, A; Sill, H
Base excision repair glycosylase activity is impaired in a subgroup of acute myeloid leukemia resulting in increased levels of oxidative base lesions
Oncol Res Treat. 2014; 37(S5):49-49.-Annual Meeting of the German, Austrian and Swiss Associations of Hematology and Medical Oncology; OCT 10-14; Hamburg, GERMANY. (ISBN: 978-3-318-02811-9 )
[Poster]
Web of Science
Rosenberger, A; Wolf, O; Zebisch, A; Touw, I; Sill, H; Wölfler, A
Myeloid progenitors contribute to formation of plasmacytoid dendritic cells in the thymus.
memo-magazine of european medical oncology
2014 Proceedings of the Annual Meeting of the Austrian Society for Haematology and Medical Oncology. 2014; 7(1):-Annual Meeting of the Austrian Society for Haematology and Medical Oncology; APR 10-12, 2014; Innsbruck, AUSTRIA.
[Poster]
Schulz, E; Klampfl, P; Holzapfel, S; Janecke, AR; Ulz, P; Renner, W; Kashofer, K; Najima, S; Leitner, A; Zebisch, A; Wölfler, A; Hofer, S; Gerger, A; Lax, S; Beham-Schmid, C; Steinke, V; Geigl, JB; Höfler, G; Speicher, MR; Boland, CR; Kumanogoh, A; Sill, H
Germline variants in the semaphorin SEMA4A confer susceptibility to familial colorectal cancer type X
Oncol Res Treat. 2014; 37(S5):105-105.-Annual Meeting of the German, Austrian and Swiss Associations of Hematology and Medical Oncology; OCT 10-14, 2014; Hamburg, GERMANY. (ISBN: 978-3-318-02811-9 )
[Oral Communication]
Web of Science
Wolf, O; Schulz, E; Theiler, G; Troppmair, J; Kolch, W; Haller, M; Woelfler, A; Sill, H; Zebisch, A
RAF kinase inhibitor protein inhibits 1,25-dihydroxyvitamin D3 induced myelomonocytic differentiation of HL-60 acute myeloid leukemia cells.
memo-magazine of european medical oncology
2014 Proceedings of the Annual Meeting of the Austrian Society for Haematology and Medical Oncology. 2014; 7(1):-Annual Meeting of the Austrian Society for Haematology and Medical Oncology; APR 10-12, 2014; Innsbruck, AUSTRIA.
[Poster]
Wölfler, A; Rosenberger, A; Wolf, O; Zebisch, A; Touw, IP; Sill, H
A role of C/EBP-Alpha in Development of Plasmacytoid Dendritic Cells in the Thymus
Haematologica. 2014; 99(S1):174-174.-19th Congress of European Hematology Association; JUN 12-15, 2014; Milan, ITALY.
[Poster]
Web of Science
Zebisch, A; Wolf, O; Rosenberger, A; Petricevic, P; Hatzl, S; Troppmair, J; Kolch, W; Blyth, K; Haller, M; Sill, H; Woelfler, A
RAF kinase inhibitor protein is involved in the regulation of myelomonocytic differentiation.
Oncol Res Treat. 2014; 37(S5):49-49. 2014; 37(S5):24-24.-Annual Meeting of the German, Austrian and Swiss Associations of Hematology and Medical Oncology; OCT 10-14; Hamburg. (ISBN: 978-3-318-0281 )
[Oral Communication]
Web of Science
Duettmann, W; Huber-Krassnitzer, B; Theiler, G; Raggam, RB; Prueller, F; Neumeister, P; Zebisch, A; Wagner, J; Seeber, K; Wölfler, A; Krause, R; Hoenigl, M.
Impact of Structured On-Site Patient Education on Low Posaconazole Plasma Concentrations.
. 2013; -53rdInterscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); SEP 10-13, 2013; Denver, USA.
[Oral Communication]
Hoenigl, M; Duettmann, W; Huber-Krassnitzer, B; Theiler, G; Raggam, RB; Prueller, F; Zebisch, A; Neumeister, P; Wagner, J; Seeber, K; Wolfler, A; Krause, R;
Impact of structured on-site patient education on low posaconazole plasma concentrations.
MYCOSES. 2013; 56: 47-47.-6th Trends in Medical Mycology; OCT 11-14, 2013; Kopenhagen, DENMARK.
[Oral Communication]
Web of Science
Zebisch, A
Molekulare Marker der Akuten myeloischen Leukämie
ÖGHO; 2013.
[Oral Communication]
Schulz, E; Valentin, A; Ulz, P; Beham-Schmid, C; Lind, K; Rupp, V; Lackner, H; Wolfler, A; Zebisch, A; Olipitz, W; Geigl, JB; Berghold, A; Speicher, MR; Sill, H
Germ-line mutations in cancer predisposing genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy-related myeloid neoplasms.
ONKOLOGIE. Onkologie. 2012; 35: 117-117.-Annual Meeting of the German, Austrian and Swiss Associations of Hematology and Medical Oncology; OCT 19-23, 2012; Stuttgart, GERMANY.
[Poster]
Web of Science
Troch, M; Kiesewetter, B; Willenbacher, W; Willenbacher, E; Zebisch, A; Linkesch, W; Fridrik, MA; Müllauer, L; Greil, R; Raderer, M
Rituximab plus subcutaneous Cladribine in patients with extranodal marginal zone B-cell Lymphoma of the Mucosa associated tissue (MALT-Lymphoma): A Phase II study by the AGMT
Annals of Oncology. 2012; 23(9):352-352.-37th ESMO Congress; SEP 28-OCT 2, 2012; VIENNA, AUSTRIA. (ISBN: 1569-8041 )
[Poster]
Web of Science
Zebisch, A; Wölfler, A; Hiden, K; Bodner, C; Fried, I; Quehenberger, F; Drasche, A; Pirkebner, D; Rath, O; Blyth, K; Matallanas, D; Taskesen, E; Kolch, W; Troppmair, J; Sill, H
RAF and RKIP in Acute Myeloid Leukemia
Fruehjahrstagung 2011 der Oesterreichischen Gesellschaft fuer Haematologie & Onkologie; Mai 5-7, 2011; Poertschach, AUSTRIA. 2011.
[Oral Communication]
Zebisch, A; Wölfler, A; Hiden K; Bodner, C; Quehenberger, F; Drasche, A; Pirkebner, D; Haller, M; Matallanas, D; Fried, I; Rath, O; Blyth, K; Taskesen, E; Kolch, W; Troppmair, J; Sill, H
RAF kinase inhibitor protein ist ein neuer Tumor-Suppressor bei der akuten myeloischen Leukämie
Onkologie. 2011; 34(S6):209-209.-Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie; SEP 30-OCT 4, 2011; Basel, Switzerland. (ISBN: 978-3-8055-9922-1 )
[Oral Communication]
Web of Science
FullText
Haller, M; Zebisch, A; Hiden, K; Hoefler, G; Sill, H; Troppmair, J
Loss of RAF kinase inhibitor protein is a somatic event in the pathogenesis of therapy-related acute myeloid leukemias with C-RAF germline mutations
FEBS J. 2010; 277: 127-127.
[Poster]
Web of Science
Zebisch, A; Woelfler, A; Hiden, K; Bodner, C; Quehenberger, F; Drasche, A; Pirkebner, D; Haller, M; Rath, O; Blyth, K; Taskesen, E; Kolch, W; Troppmair, J; Sill, H
Loss of RAF Kinase Inhibitor Protein Is a Frequent Event In Acute Myeloid Leukemia with a Monocytic Phenotype and Cooperates with Mutant RAS In Malignant Transformation
BLOOD. 2010; 116(21): 1702-1702.
[Poster]
Web of Science
Zebisch, A; Woelfler, A; Hiden, K; Bodner, C; Quehenberger, F; Drasche, A; Pirkebner, D; Rath, O; Blyth, K; Delwel, R; Taskesen, E; Kolch, W; Troppmair, J; Sill, H
LOSS OF RKIP IN ACUTE MYELOID LEUKEMIA WITH A MONOCYTIC PHENOTYPE
HAEMATOL-HEMATOL J. 2010; 95: 0026 -Annual Meting of the European Haematology Association; June 2010; Barcelona.
[Poster]
Web of Science
Zebisch, A; Haller, M; Hiden, K; Rath, O; Doyle, B; Wölfler, A; Delwel, R; Kolch, W; Troppmair, J; Sill, H
Loss of the tumor suppressor RKIP in acute myeloid leukemia
Memo2009; 2 (Suppl.2): -Frühjahrstagung der Österr. Gesellschaft für Hämnatologie und Onkologie; April 2009; Salzburg.
[Oral Communication]
Novak, M; Bernhard, H; Hiden, M; Rehak, T; Rosenkranz, A; Zebisch, A; Klaschka, S; Leschnik, B; Muntean, W
Microparticles in Plasma of Severe Thrombocytopenic Patients Support the Effect of rFVIIa on Thrombin Generation.
ZMF-Leistungsschau; NOV 12, 2008; Graz, AUSTRIA. 2008.
[Poster]
Novak, M; Rosenkranz, A; Muntean, W; Zebisch, A; Sill, H; Hiden, M
Recombinant factor VIIa enhances thrombin generation in plasma of severe thrombocytopenic patients.
HAEMOPHILIA. HAEMOPHILIA2008; 14: 9-9.-World Hemophilia Congress ; JUN 2-5, 2008; Istanbul, TÜRKEI.
[Oral Communication]
Web of Science
Novak, M; Rosenkranz, A; Rehak, T; Zebisch, A; Klaschka, S; Muntean, W
Enhancement of Thrombin Generation by rVIIa in Plasma of Severe Thrombocytopenic Patients.
52. Jahrestagung der Gesellschaft für Thrombose- und Hämostaseforschung e.V.2008; -52. Jahrestagung der Gesellschaft für Thrombose- und Hämostaseforschung e.V.; FEB 20-23, 2008; Wiesbaden, GERMANY.
[Poster]
Reitter, S; Zinke-Cerwenka, W; Zebisch, A; Sormann, S; Sill, H; Linkesch, W
Haematopoetic stem cell transplantation in CLL: promising results using allogeneic reduced intensity conditioning compared with an autologous setting
BONE MARROW TRANSPLANT. 2008; 41: S309-S310.-34th Meeting oif the EBMT; MARCH 30- APR 2, 2008; Florence, ITALY.
[Poster]
Web of Science
Zach, J; Zollner-Schwetz, I; Zebisch, A; Rohn, A; Krause, R
Mikrobiologisches Screening zur Detektion von Katheter-assoziierten Bakteriämien/Fungämien bei Patienten im Rahmen einer hämatopoetischen Stammzelltransplantation.
. 2008; 120(15): A48
[Poster]
Web of Science
Zach, J; Zollner-Schwetz, I; Zebisch, A; Rohn, A; Krause, R
Microbiological screening of catheter related blood stream infections in patients receiving HSCT
Interscience Conference on Antimicrobial Agents and Chemotherapy; October 2008; Washington, USA. 2008.
[Poster]
Zinke-Cerwenka, W; Posch, U; Zebisch, A; Linkesch, W; Sill, H
Results of umbilical cord blood transplantations in adults with high-risk haematologic malignancies
BONE MARROW TRANSPLANT. BONE MARROW TRANSPLANTATION.2008; 41: S158-S158.-34th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/24nd Meeting of the EBMT-Nurses-Group/7th Meeting of the EBMT-Data-Management-Group; MAR 30-APR 02, 2008; Florence, ITALY.
[Poster]
Web of Science
Zinke-Cerwenka, W; Stojakovic, T; Zebisch, A; Sill, H; Linkesch, W
Promising results in multiple myeloma patients treated with induction chemotherapy consisting of bortezomib, doxorubicin and dexamethasone followed by autologous stem cell transplantation
BONE MARROW TRANSPLANT. 2008; 41: S185-S185.-34th Meeting of the EBMT; March 30- APR 2, 2008;
[Poster]
Web of Science
Novak, M; Hiden, M; Rehak, T; Rosenkranz, A; Zebisch, A; Klaschka, S; Muntean, W
rVIIa enhances thrombin generation in plasma of severe thrombocytopenic patients.
38. Hämophili Symposium ; NOV 9-10, 2007; Hamburg, GERMANY. 2007.
[Oral Communication]
Reitter, S; Zinke-Cerwenka, W; Zebisch, A; Sill, H; Linkesch, W
Haematopoietic stem cell transplantation in CLL
ACA Acta Chirurgica Austriaca - European Surgery2007; 39(218):29-29.-21st Meeting of the Austrian Society of Transplantation, Transfusion and Genetics; OCT 17-20, 2007; St. Wolfgang.
[Poster]
Zinke-Cerwenka, W; Posch, U; Zebisch, A; Strunk, D; Linkesch, W; Sill, H
Outcome of umbilical cord blood transplanatations in adults with high-risk hematologic malignancies
ACA Acta Chirurgica Austriaca - European Surgery2007; 39(218):42-42.-21st Meeting of the Austrian Society of Transplantation, Transfusion and Genetics; OCT 17-20, 2007; St. Wolfgang, Austria.
[Poster]
Zinke-Cerwenka, W; Stojakovic, T; Zebisch, A; Strunk, D; Sill, H; Linkesch, W
First-line therapy in multiple myeloma patients with bortezomib, doxorubicin and dexamethasone followed by autologous stem cell
ACA Acta Chirurgica Austriaca - European Surgery2007; 39(218):42-42.-21st Meeting of the Austrian Society of Transplantation, Transfusion and Genetics; OCT 17-20, 2007; St. Wolfgang, Austria.
[Poster]
Langner, S; Staber, PB; Zebisch, A; Triebl-Roth, K; Urban, C; Zinke-Cerwenka, W; Sill, H; Linkesch, W; Neumeister, P
Reduced oral mucositis and enhanced intestinal mucosal recovery measured by citrulline serum levels in allogeneic and autologous stem cell transplant recipients treated with palifermin
Onkologie. 29(S3):125-126.-German, Austrian and Swiss Societies of Hematology and Oncology; NOV 4-8, 2006; Leipzig, GERMANY.
[Poster]
Langner, S; Staber, PB; Zebisch, A; Zinke-Cerwenka, W; Sill, H; Linkesch, W; Greinix, H; Kalhs, P; Rabitsch, W; Neumeister, P
Adding palifermin in allogeneic and autologous stem cell transplantation resulted in reduced oral mucositis and enhanced intestinal mucosal recovery measured by citrulline serum levels.
BLOOD. 2006; 108(11): 404B-404B.
Doi: 10.1182/blood.V108.11.5251.5251
[Poster]
Web of Science
FullText
FullText_MUG
Zebisch, A; Ofner, P; Sill, H; Linkesch, W; Krause, R; Auner, HW;
Risk factors for early infectious complications after autologous peripheral blood stem cell transplantation in patients with hematopoietic malignancies.
Onkologie. 2004; 27: 8-8.
[Poster]
Zebisch, A; Ofner, P; Sill, H; Linkesch, W; Krause, R; Auner, HW;
Analysis of risk factors for early infectous complications after autologous peripheral blood stem cell transplantation in patients with hematopoietic malignancies.
Acta Chir Aust. 2004; 36: 17-17.
[Poster]
Zebisch, A; Staber, PB; Fischereder, K; Bodner, C; Hiden, K; Linkesch, W; Auner, HW; Emberger, W; Sovinz, P; Schimek, MG; Höfler, G; Sill, H;
Analysis of the proto-oncogenes A-, B- and C-RAF in acute myeloid leukemia.
The Hematol J. 2004; 5: 2-2.
[Poster]
Zebisch, A; Staber, PB; Fischereder, K; Bodner, C; Hiden, K; Linkesch, W; Auner, HW; Emberger, W; Windpassinger, C; Schimek, MG; Hoefler, G; Troppmair, J; Sill, H
Two novel activating germline mutations of the C-RAF proto-oncogene predisposing to solid tbmors and therapy-related acute myeloid leukemia.
BLOOD 2004 104: 920A-920A.
Doi: 10.1182/blood.V104.11.3370.3370
Web of Science
FullText
FullText_MUG
Zebisch, A; Staber, PB; Fischereder, K; Bodner, C; Hiden, K; Linkesch, W; Auner, HW; Windpassinger, C; Höfler, G; Sill, H;
C-RAF mutations in therapy-related acute myeloid leukemia.
Onkologie. 2004; 27: 118-118.
[Poster]
Zebisch, A; Staber,P; Fischeneder,K; Bodner,C; Hiden,K; Linkesch,W; Auner,H; Emberger,W; Sovinz,P; Schirnek,M; Höfler, G; Sill,H.
C-RAF Mutationen und B-RAF Gen Deletion bei therapieassoziierter akuter myeloischer Leukämie
98.Hämatologisch-Onkologischer Diskussionsabend der Österr. Gesellschaft für Hämatologie und Onkologie; JUNI. 17, 2004; Wien, AUSTRIA. 2004.
[Keynote lecture]
Zebisch,a; Staber,PB; Fischereder,K; Bodner,C; Hiden,K; Linkesch,W; Auner,HW; Emberger,W; Sovinz,P; Schimek,MG; GHöfler,G; Sill,H;
C-RAF missense mutations and B-RAF gene deletion in therapy related acute myeloid leukemia.
Acta Med Aust. 2004; 31: 9-9.
[Keynote lecture]
Auner,HW; Zebisch,A; Schimek,G; Bodner,C; Hiden,kK, Linkesch,W; Haas,OA; Sill,H;
Analysis of the sister-chromatid separation regulator and proto-oncogene hSecurin in myeloid leukemias.
Proceedings of the 17th meeting of the Int.Soc of Haematology2003; 22-22.-17th meeting of the Int.Soc of Haematology; SEP 7-10, 2003; Graz,AUSTRIA.
[Poster]
Zebisch, A; Staber,PB; Fischereder,K; Bodner,C; Hiden,K; Linkesch,W; Auner,HW; Emberger,W; Sovinz,P; Schimek,MG; Höfler,G; Sill,H;
C-RAF missense mutations and B-RAF gene deletion in therapy-related acute myeloid leukemia.
Acta Med Aust. 2003; 31(5):9-9.- ; ; .
[Poster]